BioFab Ltd ^Company

BioFab develops innovative new products for health care diagnostics, focusing on point-of-care testing (POCT) applications. The company produced its diagnostic platform and sought to implement rapid tests for infectious disease, including Covid-19. It is designed to be flexible such that tests for new strains can be developed quickly. Tests based on the detection of viral RNA, the protein antigen itself, and host antibodies related to immunity, all on the same platform, are planned. BioFab secured an Innovate UK SMART award and is seeking further investment to accelerate the development. The company is skilled in the design and development of consumable cartridges based on microfluidic technology. BioFab has bio-deposition facilities in-house and expertise in antibody spotting onto diagnostic membranes and surfaces.